

- Cassel EJ. The nature of suffering and the goals of medicine. *N Engl J Med* 1982;306:639–645.
- Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. *N Engl J Med* 2012;367:1616–1625.
- Mitera G, Zhang A, Sahgal E, et al. A survey of expectations and understanding of palliative radiotherapy from patients with advanced cancer. *Clin Oncol* 2012;24:134–138.
- Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. *JAMA* 2009;302:741–749.
- Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733–742.
- Steinhauser K, Clipp EC, McNeilly M, et al. In search of a good death: observations of patients, families, and providers. *Ann Intern Med* 2000;132:825–832.
- Muers MF, Round CE. Palliation of symptoms in non-small-cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. *Thorax* 1993;48:339–343.
- Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. *J Pain Symptom Manage* 1998;16:212–219.
- Peiffer C, Poline J, Thivard L, et al. Neural substrates for the perception of acutely induced dyspnea. *Am J Respir Crit Care Med* 2001;163:951–957.
- Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. *Am J Crit Care* 1998;7:200–204.
- Bruera E, de Stoutz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnea in hypoxaemic terminal-cancer patients. *Lancet* 1993;342:13–14.
- Light RW, Muro JR, Sato RI, et al. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1989;139:126–133.
- Bruera E, MacEachern T, Ripamonti C, et al. Subcutaneous morphine for dyspnea in cancer patients. *Ann Intern Med* 1993;119:906–907.
- Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilator function in elderly patients with advanced cancer: a randomized double-blind controlled trial. *Ann Oncol* 1999;10:1511–1514.
- Mitchell-Heggs P, Murphy K, Minty K, et al. Diazepam in the treatment of dyspnea in the 'pink puffer' syndrome. *QJ Med* 1980;49:9–20.
- Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. *J Pain Symptom Manage* 2007;34:S49–S59.
- Ripamonti C. Management of bowel obstruction in advanced cancer. *Curr Opin Oncol* 1994;6:351–357.
- Mercadante S, Caraceni A, Simonetti MJ. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. *Palliative Medicine* 1993;7:295–299.
- Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. *J Pain Symptom Manage* 2000;19:23–34.
- Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. *Support Care Cancer* 2000;8:188–191.
- Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. *Ann Oncol* 1999;10:1035–1041.
- Feuer DJ, Broadley KE, Shepherd JH, et al. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. *Gynecol Oncol* 1999;75:313–322.
- Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. *Support Care Cancer* 2001;9:223–233.
- Aranha GV, Folk FA, Greenlee HB. Surgical palliation of small bowel obstruction due to metastatic carcinoma. *Am Surg* 1981;47:99–102.
- Legendre H, Vahhuyse F, Caroli-Bose FX, et al. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. *Eur J Surg* 2001;27:364–367.
- Miner TJ, Jaques DP, Shriver CD. A prospective evaluation of patients undergoing surgery for the palliation of an advanced malignancy. *Ann Surg Oncol* 2002;9:696–703.
- Makela J, Kiviniemi H, Laitinen S, et al. Surgical management of intestinal obstruction after treatment for cancer. *Eur J Surg* 1991;157:73–77.
- Campagnutta E, Cannizzaro R. Percutaneous endoscopic gastrostomy (PEG) in palliative treatment of non-operable intestinal obstruction due to gynecologic cancer: a review. *Eur J Gynaecol Oncol* 2000;21:397–402.
- Badgwell BD, Contreras C, Askew R, et al. Radiographic and clinical factors associated with improved outcomes in advanced cancer patients with bowel obstruction. *J Palliat Med* 2011;14:990–996.
- Harris CJ, Senagore AJ, Lavery IC, et al. The management of neoplastic colorectal obstruction with colonic endoluminal stenting devices. *Am J Surg* 2001;181:499–506.
- Soetikno RM, Carr-Locke DL. Expandable metal stents for gastric outlet, duodenal, and small intestinal obstruction. *Gastrointest Endosc Clin N Am* 1999;9:447–458.
- Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. *J Pain Symptom Manage* 2014;47:307–314.
- Potts JR III, Broughan TA, Hermann RE. Palliative operations for pancreatic carcinoma. *Am J Surg* 1990;159:72–78.
- Krouse RS. Advances in palliative surgery for cancer patients. *J Suppl Oncol* 2004;2:80–87.
- Kaw M, Singh S, Gagneja H, et al. Role of self-expandable metal stents in the palliation of malignant duodenal obstruction. *Surg Endosc* 2003;17:646–650.
- Kim JH, Yoo BM, Lee KJ, et al. Self-expanding coil stent with a long delivery system for palliation of unresectable malignant gastric outlet obstruction: a prospective study. *Endosc* 2001;33:838–842.
- Choi YB. Laparoscopic gastrojejunostomy for palliation of gastric outlet obstruction in unresectable gastric cancer. *Surg Endosc* 2002;16:1620–1626.
- Lucas CE, Ledgerwood AM, Bender JS. Antrectomy with gastrojejunostomy for unresectable pancreatic cancer-causing duodenal obstruction. *Surg* 1991;110:583–590.
- Coene PPO, Huijbregt K, van Gulck TM, et al. Duodenal obstruction requiring surgery following endoscopic palliation in patients with pancreatic local tumors. *Neth J Med* 1994;45:A28.
- Holbrook AG, Chester JF, Britton DC. Surgical palliation for pancreatic cancer: will biliary bypass alone suffice? *J R Soc Med* 1990;83:12–14.
- Huguier M, Baumel H, Manderscheid JC, et al. Surgical palliation for unresected cancer of the exocrine pancreas. *Eur J Surg Oncol* 1993;19:342–347.
- Takeyoshi I, Makita F, Iwazaki S, et al. Weekly paclitaxel in combination with doxorubicin for peritoneally disseminated gastric cancer with malignant ascites. *Anticancer Res* 2011;31:4625–4630.
- Imamoto H, Oba K, Sakamoto J, et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. *Gastric Cancer* 2011;14:81–90.
- Jia W, Zhu Z, Zhang T, et al. Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. *Cancer Chemother Pharmacol* 2013;71:1585–1590.
- Cavazzoni E, Bugiantella W, Graziosi L, et al. Malignant ascites: pathophysiology and treatment. *Int J Clin Oncol* 2013;18:1–9.
- Frampton JE. Catumaxomab in malignant ascites. *Drugs* 2012;72:1399–1410.
- Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncol* 2012;13:154–162.
- Colombo N, Mangili G, Mammoliti S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. *Gynecol Oncol* 2012;125:42–47.
- Mercadante S, La Rosa S, Nicolosi G, et al. Temporary drainage of symptomatic malignant ascites by a catheter inserted under computerized tomography. *J Pain Symptom Manage* 1998;15:374–378.
- O'Neill MJ, Weissleder R, Gervais DA, et al. Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites. *Am J Roentgenol* 2001;177:615–618.
- Barnett TD, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach. *J Vasc Interv Radiol* 2002;13:379–383.
- Richard HM III, Coldwell DM, Boyd-Kranis RL, et al. Pleurx tunneled catheter in the management of malignant ascites. *J Vasc Interv Radiol* 2001;12:373–375.
- Iyengar TD, Herzog TJ. Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. *Am J Hosp Palliat Care* 2002;19:35–38.
- Rosenblum DI, Geisinger MA, Newman JS, et al. Use of subcutaneous venous access ports to treat refractory ascites. *J Vasc Interv Radiol* 2001;12:1343–1346.
- Kuruvillea A, Busby G, Ramsewak S. Intraoperative placement of a self-retaining Foley catheter for continuous drainage of malignant ascites. *Eur J Gynaecol Oncol* 2002;23:68–69.
- Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. *Support Care Cancer* 2000;8:493–499.
- Kirk IR, Carrasco CH, Lawrence DD, et al. Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance. *J Vasc Interv Radiol* 1993;4:299–304.
- Smith DA, Weaver DW, Bouwman DL. Peritoneovenous shunt (PVS) for malignant ascites. *Am Surg* 1989;55:445–449.
- Zanon C, Grosso M, Apra F, et al. Palliative treatment of malignant retractor ascites by positioning of Denver peritoneovenous shunt. *Tumori* 2002;88:123–127.
- Bieligk SC, Calvo BF, Coit DG. Peritoneovenous shunting for nongynecologic malignant ascites. *Cancer* 2001;91:1247–1255.

61. Sugawara S, Sone M, Arai Y, et al. Radiological insertion of Denver peritoneovenous shunts for malignant refractory ascites: a retrospective multicenter study (JIVROSG-0809). *Cardiovasc Intervent Radiol* 2011;34:980–988.
62. Valle M, van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal preoperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. *J Surg Oncol* 2009;100:331–334.
63. Facchian E, Risio D, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. *Ann Surg Oncol* 2012;19:2946–2950.
64. Loggie BW, Fleming RA, McQuellon RP, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. *Am Surg* 2000;66:561–568.
65. McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. *Ann Surg Oncol* 2007;14:1105–1113.
66. Ong E, Diven C, Abrams A, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for palliative treatment of malignant ascites from gastrointestinal stromal tumours. *J Palliat Care* 2012;28:293–296.
67. Cui S, Ba M, Tang Y, et al. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. *Oncol Rep* 2012;28:1325–1331.
68. Badgwell BD, Smith K, Liu P, et al. Indicators of surgery and survival in oncology inpatients requiring surgical evaluation for palliation. *Support Care Cancer* 2009;17:727–734.
69. Cheung KL, Willsher PC, Robertson JF, et al. Omental transposition flap for gross locally recurrent breast cancer. *Aust N Z J Surg* 1997;67:185–186.
70. Flook D, Webster DJ, Hughes LE, et al. Salvage surgery for advanced local recurrence of breast cancer. *Br J Surg* 1989;76:512–514.
71. Sweetland HM, Karatsis P, Rogers K. Radical surgery for advanced and recurrent breast cancer. *J R Coll Surg Edinb* 1995;40:88–92.
72. Downey RJ, Rusch V, Hsu FI, et al. Chest wall resection for locally recurrent breast cancer: is it worthwhile? *J Thorac Cardiovasc Surg* 2000;119:420–428.
73. Henderson MA, Burt JD, Jenner D, et al. Radical surgery with omental flap for uncontrolled locally recurrent breast cancer. *Aust N Z J Surg* 2001;71:675–679.
74. Paz IB. Major palliative amputations. *Surg Oncol Clin N Am* 2004;13:543–547.
75. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion in regional melanoma. *Surg Oncol Clin N Am* 2006;15:373–384.
76. Lund-Nielsen B, Muller K, Adamsen L. Malignant wounds in women with breast cancer: feminine and sexual perspectives. *J Clin Nurs* 2004;14:56–64.
77. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. *JAMA* 1995;274:1591–1598.
78. Hardin SB, Yusufaly YA. Difficult end-of-life treatment decisions: do other factors trump advance directives? *Arch Intern Med* 2004;164:1531–1533.
79. Ellershaw J, Ward C. Care of the dying patient: the last hours or days of life. *BMJ* 2003;326:30–34.
80. Adam J. ABC of palliative care. The last 38 hours. *BMJ* 1997;315:1600–1603.
81. Plonk WM Jr, Arnold RM. Terminal care: the last weeks of life. *J Palliat Med* 2005;8:1042–1054.